OVAS OvaScience Inc

EQUITY ALERT: Rosen Law Firm Announces Investigation of Claims Against OvaScience, Inc.

NEW YORK--(BUSINESS WIRE)--

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential claims on behalf of shareholders of OvaScience, Inc. (NASDAQ:OVAS) resulting from allegations that OvaScience may have issued materially misleading business information to the investing public.

This investigation concerns whether OvaScience made materially untrue and misleading statements and omitted material information due to OvaScience’s alleged failure to disclose that OvaScience’s AUGMENT procedure did not attain a substantial success rate of clinical pregnancies compared to rates attained without OvaScience’s AUGMENT procedure.

If you purchased shares of OvaScience, please visit the firm’s website at http://rosenlegal.com/cases-1256.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.

EN
15/12/2017

Underlying

OVASOvaScience Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OvaScience Inc

 PRESS RELEASE
Free
OVAS OVASCIENCE INC

OvaScience Reports First Quarter 2018 Financial Results and Provides B...

WALTHAM, Mass.--(BUSINESS WIRE)-- OvaScienceSM (Nasdaq:OVAS), a company focused on the development of new treatment options for women and couples struggling with infertility, today reported financial results for the first quarter ended March 31, 2018 and provided a business update. OvaScience is completing preclinical studies designed to evaluate its egg precursor (EggPCSM) cell technology platform and inform the future development of OvaPrime. Based on preliminary data from these experiments and those of OvaScience’s academi...

May 3, 2018 1 EN
 PRESS RELEASE
Free
OVAS OVASCIENCE INC

OvaScience Reports Fourth Quarter and Year-End 2017 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)-- OvaScienceSM (NASDAQ:OVAS), a company focused on the discovery and development of new treatment options for women and families struggling with infertility, today reported financial results and provided a business update for the fourth quarter and year ended December 31, 2017. “We made a concerted effort over the past six months to hone our strategic focus on research and development, and are positioned to make meaningful progress in our OvaPrime and OvaTure programs in 2018,” said Dr. ...

March 15, 2018 1 EN
 PRESS RELEASE
Free
OVAS OVASCIENCE INC

OvaScience Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(...

WALTHAM, Mass.--(BUSINESS WIRE)-- OvaScienceSM, Inc. (NASDAQ: OVAS), a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility, today announced the grant of an inducement award to its newly appointed Chief Scientific Officer, James W. Lillie, Ph.D. The award was approved by OvaScience’s Board of Directors on March 6, 2018 as an inducement material to Dr. Lillie entering into employment with the Company, as permitted under Nasdaq Listing Rule 5635(c...

March 12, 2018 1 EN
 PRESS RELEASE
Free
OVAS OVASCIENCE INC

OvaScience to Host Fourth Quarter and Fiscal Year 2017 Financial Resul...

WALTHAM, Mass.--(BUSINESS WIRE)-- OvaScience℠ (NASDAQ: OVAS), a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility, today announced that it will host a conference call at 4:30 p.m. ET on Thursday, March 15, 2018 to discuss fourth quarter and fiscal year 2017 financial results and provide a general corporate update. The conference call may be accessed by dialing +1-888-424-8151 for U.S. callers and +1-847-585-4422 for international cal...

March 8, 2018 1 EN
 PRESS RELEASE
Free
OVAS OVASCIENCE INC

OVASCIENCE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors W...

NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in OvaScience, Inc. (“OvaScience” or the “Company”) (NASDAQ:OVAS) of the January 22, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in OvaScience stock or options in the Company’s Secondary Offering on or about January 8, 2015 (the “Secondary Offering”) and would like to discuss your legal rights, click here: www.faruq...

January 17, 2018 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch